Homechevron_rightAll Peptideschevron_rightSemaglutide Injection Pen

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-semaglutide-injection-pen-10mg

Official Product Data Sheet

Semaglutide Injection Pen (10mg)

High >98% Purity

Vial Contents

10 mg Semaglutide (3 mL pre-filled injection pen)

Includes

Ready-to-use multi-dose injection pen — no mixing or reconstitution required

Form

Pre-filled multi-dose pen

Purity

≥98%, third-party verified

Sequence

GLP-1 Analog

Molecular Formula

See chemical properties

Molecular Mass

≈4113.64 g/mol

CAS No.

910463-68-2

Solubility

Concentration: ≈3.33 mg/mL | Per click: 1 unit ≈ 33.33 mcg (0.033 mg)

Storage

Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

swipe_rightSwipe to see all tabs

Scientific Background

Semaglutide is an extended-duration GLP-1 receptor agonist that echoes a native intestinal hormone to regulate appetite and metabolic processes. The 10 mg pre-filled pen connects to receptors in the brain and digestive system to lessen hunger, postpone gastric clearance, and heighten insulin response tied to glucose levels — guaranteeing effortless weekly under-skin delivery for reliable examination of hunger regulation and metabolic adjustments. At twice the concentration of the 5 mg pen, it provides up to double the per-pen duration at equivalent doses.

Intended Research Use

Appetite suppression and satiety regulation research
GLP-1 receptor binding and signaling studies
Glucose metabolism and insulin sensitivity research
Lipid profile and cardiovascular marker improvement
Extended weight loss cycle research (higher dose economy)

menu_bookScientific Publications

article

N Engl J Med (2021)

Once-Weekly Semaglutide in Adults with Overweight or Obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33567185/

article

JAMA (2021)

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33625476/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Semaglutide combines synergistically with peptides targeting complementary weight loss and metabolic pathways.

Cagrilintide 10mg (10mg vial)

arrow_forward

myo-cagrilintide-10mg

Intensified satiety and accelerated weight reduction — Cagrilintide's amylin analog action complements Semaglutide's GLP-1 appetite suppression through additive pathways.

AOD-9604 5mg (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targeted fat-zone lipolysis — AOD-9604 directly stimulates breakdown in stubborn adipose areas while Semaglutide controls appetite and systemic metabolism.

Retatrutide 10mg (10mg vial)

arrow_forward

myo-retatrutide-10mg

Multi-pathway fat dissolution — Retatrutide's triple GIP/GLP-1/glucagon agonism adds complementary mechanisms to Semaglutide's established GLP-1 efficacy.

schedule

Cycling Note: Typical protocol: 16–52 weeks with gradual titration every 4 weeks. Allow adequate washout period between cycles when discontinuing.

Also Available

Vial

Semaglutide

5mg

Vial

Semaglutide

10mg

Pen

Semaglutide Injection Pen

5mg